MISSION
Mirum Pharmaceuticals is a biopharmaceutical company dedicated to transforming the treatment of rare diseases. We are passionate about advancing scientific discoveries to become important medicines for rare disease patients. We are collaborative, creative, and experienced professionals and we’re looking to augment our team with other individuals who embody our values: care, be real, get it done, and have fun, seriously.
POSITION SUMMARY
We are seeking a highly motivated Manager of Commercial Analytics to join our growing company and portfolio of products. The Manager will be responsible for providing strategic insights and analysis to support decision-making across our rare disease portfolio, specializing on the patient journey and reimbursement hub and pharmacy operations metrics. This role may also involve obtaining and analyzing secondary market data, monitoring commercial performance, identifying key drivers of success, and conducting ad hoc analysis to drive business growth. Candidates with an appropriate level of experience may be considered for a more advanced position.
JOB FUNCTIONS/RESPONSIBILITIES
- Design key performance metrics associated with the patient journey, including patient support success metrics, insurance approval metrics, and pharmacy performance metrics
- Liaise with Patient Services, Sales, Information Technology, and outside vendors associated with the company’s Salesforce and other CRM systems
- Monitor and report on the patient journey and other commercial performance metrics on a regular basis (daily, weekly, monthly, quarterly) and identify any trends that require action.
- Work together with the Commercial Analytics team to present a comprehensive view of commercial performance across the company’s product portfolio and books of business.
- Collaborate with cross-functional teams to understand commercial reporting needs
- Design and build commercial reporting dashboards for multiple functional audiences at the company, ensuring that our commercial team has the information they need to monitor performance vs goals
- Conduct ad hoc analytics to support key business initiatives, such as product launches, market expansions, and internal business reviews
- Analyze secondary market data to identify potential market size, key prescribers, patient demographics, and competitive landscape in multiple disease indications
- Present findings in a very clear and concise manner to internal stakeholders and senior leadership
QUALIFICATIONS
- Bachelor's degree in a Life Sciences discipline strongly preferred, though degrees in Business, Economics, or related fields will be considered
- MBA or other Master’s Degree is a plus
- Minimum of 5 years of experience in the bio-pharmaceutical industry in commercial analytics, and experience in rare disease fields strongly preferred
- Exceptional Analytics skills, with the ability to deliver exactly the right information in way that is easily interpreted and understood.
- Experience with Komodo claims data or other claims data vendors
- Experience with data reporting platforms such as Power BI or Tableau
Knowledge, Skills and Abilities:
- Ability to work with and understand multiple constituencies at the company, including Executive Leadership, Sales Leadership, Sales professionals, Marketing, Medical, and Finance.
- Expert level proficiency in Microsoft Excel and Power Point
- Excellent communication and listening skills – ensure you understand what the customer really wants
- Very strong presentation skills required. You will need to deliver the results of your research appropriately to the audience in question, with the ability to anticipate (and answer) questions during your presentations.
- Ability to thrive in a fast-paced, dynamic environment. The job will be different day to day, and the successful candidate will thrive on change and the ability to respond to unanticipated projects.
The salary range for this position is $140,000 to $150,000 USD. Compensation will be determined based on several factors including, but not limited to; skill set, years of experience, and the employee’s geographic location. Please note that the required compensation details listed in US role postings reflect the base salary only, and do not include bonus, equity, or benefits unless otherwise provided.
#LI-HYBRID
Mirum Pharmaceuticals is committed to Equal Employment Opportunity (EEO) and to compliance with all Federal, State and Local laws that prohibit employment discrimination on the basis of race, age, national origin, ethnicity, religion, gender, gender identity, pregnancy, marital status, sexual orientation, citizenship, genetic disposition or characteristics, disability, veteran’s status or any other classification protected by applicable State/Federal/Local laws.
Mirum Pharmaceuticals provides reasonable accommodation for qualified individuals with disabilities and disabled veterans in job application procedures.
Top Skills
What We Do
Mirum Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to transforming the treatment of rare diseases. Mirum’s approved medication is LIVMARLI® (maralixibat) oral solution which is approved in the U.S. for the treatment of cholestatic pruritus in patients with Alagille syndrome one year of age and older.
Mirum’s late-stage pipeline includes two investigational treatments for debilitating liver diseases affecting children and adults. Maralixibat (LIVMARLI), an oral ileal bile acid transporter (IBAT) inhibitor, is currently being evaluated in clinical trials for pediatric liver diseases and includes the MARCH Phase 3 study for progressive familial intrahepatic cholestasis (PFIC) and the EMBARK Phase 2b study for patients with biliary atresia. In addition, Mirum has an expanded access program open in Canada, Australia, the UK and several countries in Europe for eligible patients with Alagille syndrome.
Mirum has submitted a Marketing Authorization Application to the European Medicines Agency for maralixibat for the treatment of cholestatic liver disease in patients with Alagille syndrome.
Mirum’s second investigational treatment, volixibat, also an oral IBAT inhibitor, is being evaluated in three potentially registrational studies including the OHANA Phase 2b study for pregnant women with intrahepatic cholestasis of pregnancy, VISTAS Phase 2b study for adults with primary sclerosing cholangitis, and the VANTAGE Phase 2b study for primary biliary cholangitis.
